

# BGT007H Cells for the Treatment of Recurrent/Refractory Gastrointestinal Tumors

NCT06152757

---

Status	RECRUITING
Phase	Early Phase 1
Sponsor	BioSyngen Pte Ltd
Enrollment	14 participants

## Key Eligibility Criteria

---

### Inclusion (10)

- \. Resources sign written informed consent;
- , age e18, male and female can;
- \. Expected survival e3 months;
- \. The Eastern Cancer Collaboration (ECOG) physical status score was 0-1;
- \. Biopsy specimen or pathological wax section test (within 3 years before accepting the signed informed consent) : positive target test;
- ... and 5 more (see full listing online)

### Exclusion (17)

- \. Active central nervous system metastasis (except stable after treatment);
- , HIV positive, HBsAg positive simultaneously detected HBV DNA copy number positive (quantitative detection e1000cps/ml), HCV antibody positive and HCV RNA positive;
- , mental or mental illness can not cooperate with treatment and efficacy evaluation;
- \. Subjects with severe autoimmune diseases and long-term use of immunosuppressants;
- \. Active or uncontrollable infection requiring systemic treatment within 14 days prior to enrollment;
- ... and 12 more (see full listing online)

## Locations (1 total)

---

The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China